CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS
3.4.1. Patent analysis by year
3.4.2. Patent analysis by region
3.5. PORTERS FIVE FORCES ANALYSIS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.2. Restraints
3.6.3. Opportunities
CHAPTER 4 GLOBAL EPIGENETICS MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size & forecast
4.2. KITS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast
4.2.4. ChIP sequencing Kits
4.2.4.1. Market size and forecast
4.2.5. Bisulfite conversion kits
4.2.5.1. Market size and forecast
4.2.6. Whole genome amplification kits
4.2.6.1. Market size and forecast
4.2.7. 5-hmC & 5-mC analysis kits
4.2.7.1. Market size and forecast
4.2.8. RNA sequencing kits
4.2.8.1. Market size and forecast
4.2.9. Other epigenetics kits
4.2.9.1. Market size and forecast
4.3. REAGENTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast
4.3.4. Antibodies
4.3.4.1. Market size and forecast
4.3.5. Magnetic beads
4.3.5.1. Market size and forecast
4.3.6. Histones
4.3.6.1. Market size and forecast
4.3.7. Buffers
4.3.7.1. Market size and forecast
4.3.8. Primers
4.3.8.1. Market size and forecast
4.3.9. Other epigenetics reagents
4.3.9.1. Market size and forecast
4.4. ENZYMES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size & forecast
4.4.4. DNA Polymerase
4.4.4.1. Market size and forecast
4.4.5. Other DNA-modifying enzymes
4.4.5.1. Market size and forecast
4.4.6. DNA ligase
4.4.6.1. Market size and forecast
4.4.7. Methyltransferase
4.4.7.1. Market size and forecast
4.4.8. Acetylase
4.4.8.1. Market size and forecast
4.4.9. Reverse transcriptase
4.4.9.1. Market size and forecast
4.4.10. Other protein-modifying enzymes
4.4.10.1. Market size and forecast
4.4.11. RNA ligase
4.4.11.1. Market size and forecast
4.4.12. Other RNA-modifying enzymes
4.4.12.1. Market size and forecast
4.5. INSTRUMENTS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size & forecast
4.5.4. Next generation sequencer
4.5.4.1. Market size and forecast
4.5.5. qPCR
4.5.5.1. Market size and forecast
4.5.6. Mass spectrometer
4.5.6.1. Market size and forecast
4.5.7. Sonicator
4.5.7.1. Market size and forecast
4.5.8. Other instruments
4.5.8.1. Market size and forecast
CHAPTER 5 ENERGY EPIGENETICS MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size & forecast
5.2. ONCOLOGY
5.2.1. Market size & forecast
5.2.1. Solid tumor
5.2.1.1. Market size and forecast
5.2.2. Liquid tumor
5.2.2.1. Market size and forecast
5.3. NON-ONCOLOGY
5.3.1. Market size & forecast
5.3.2. Metabolic disease
5.3.2.1. Market size and forecast
5.3.3. Infectious disease
5.3.3.1. Market size and forecast
5.3.4. Inflammatory disease
5.3.4.1. Market size and forecast
5.3.5. Cardiovascular disease
5.3.5.1. Market size and forecast
5.3.6. Other applications
5.3.6.1. Market size and forecast
CHAPTER 6 GLOBAL EPIGENETICS MARKET, BY END USERS
6.1. OVERVIEW
6.1.1. Market size & forecast
6.2. ACADEMIC & GOVERNMENT RESEARCH INSTITUTE
6.2.1. Market size & forecast
6.3. PHARMACEUTICAL COMPANY
6.3.1. Market size & forecast
6.4. BIOTECHNOLOGY COMPANY
6.4.1. Market size & forecast
6.5. CONTRACT RESEARCH ORGANIZATION (CRO)
6.5.1. Market size & forecast
CHAPTER 7 EPIGENETICS MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. ILLUMINA, INC
8.1.1. Operating business segments
8.1.2. Business performance
8.2. THERMO FISHER SCIENTIFIC, INC
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. ABCAM PLC
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. EPIZYME, INC.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. NEW ENGLAND BIOLABS, INC. (NEB)
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. QIAGEN N.V.,
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. MERCK & CO., (MERCK)
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. ACTIVE MOTIF
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. DIAGENODE, INC.
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. ZYMO RESEARCH CORPORATION (ZYMO)
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments